scholarly journals A99 COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS

2019 ◽  
Vol 2 (Supplement_2) ◽  
pp. 197-198
Author(s):  
C L Beilman ◽  
R Fedorak ◽  
B Halloran
Keyword(s):  
Ulcerative Colitis ◽  
Cost Effectiveness ◽  
First Line ◽  
Severe Ulcerative Colitis

scholarly journals Sa1029 – Cost-Effectiveness of First-Line Biologics for the Management of Moderate-To-Severe Ulcerative Colitis

2019 ◽  
Vol 156 (6) ◽  
pp. S-260-S-261
Author(s):  
Candace L. Beilman ◽  
Richard N. Fedorak ◽  
Brendan P. Halloran
Keyword(s):  
Ulcerative Colitis ◽  
Cost Effectiveness ◽  
First Line ◽  
Severe Ulcerative Colitis

scholarly journals Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany

2021 ◽  
Vol 24 (1) ◽  
pp. 279-290
Author(s):  
Aditya Sardesai ◽  
Axel Dignass ◽  
Peter Quon ◽  
Sandra Milev ◽  
Joseph C. Cappelleri ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Cost Effectiveness ◽  
Severe Ulcerative Colitis

scholarly journals PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN

2019 ◽  
Vol 22 ◽  
pp. S619 ◽  
Author(s):  
L. Menchén ◽  
F. de Andrés-Nogales ◽  
S. García ◽  
A. Sánchez-Guerrero ◽  
B. Menchen ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Cost Effectiveness ◽  
Severe Ulcerative Colitis

Sa1108 Cost-Effectiveness of Golimumab Versus Infliximab and Adalimumab for the Treatment of Moderate to Severe Ulcerative Colitis

2014 ◽  
Vol 146 (5) ◽  
pp. S-202 ◽  
Author(s):  
Kristian Thorlund ◽  
Eric Druyts ◽  
Steve Kanters ◽  
Shawn Eapen ◽  
Edward Mills
Keyword(s):  
Ulcerative Colitis ◽  
Cost Effectiveness ◽  
Severe Ulcerative Colitis
Sign in / Sign up

Export Citation Format

Share Document